CURRENT
ISSUE
1638

The FDA has issued an Emergency Use Authorization (EUA) for a lower-strength (10 mcg/0.2 mL) formulation of the mRNA-based COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) for use in children 5-11 years old.1 The original formulation of Comirnaty (30 mcg/0.3 mL) is FDA-licensed for use in persons ≥16 years old and available under an EUA for use in adolescents 12-15 years old.2,3

CLINICAL STUDIES — A study compared the immunogenicity of a 10-mcg dose of Comirnaty in 264 children 5-11 years old with that of a 30-mcg dose in 253 persons 16-25 years old. Geometric mean titer levels of...  Continue reading

More from Issue 1638
Previous Issue: 1637      November 15, 2021
Coming Soon
Antiviral Drugs for Influenza for 2021-2022
Drugs for Alcohol Use Disorder
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
Bupivacaine/meloxicam (Zynrelef) for Pain
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a booster dose for all adults ≥18 years old after primary immunization with either the same COVID-19 vaccine or a different one. Booster doses of these vaccines were previously ... Continue reading

 Tweets